Peer-reviewed veterinary case report
S100A4 protein linked to aggressive canine mammary cancer cells
By Yoshimura, Hisashi et al.·Published in Veterinary pathology·2019·Department of Applied Science, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Expression and Roles of S100A4 in Anaplastic Cells of Canine Mammary Carcinomas.
- Species:
- dog
Plain-English summary
A study looked at a specific protein called S100A4 in dogs with mammary tumors, which can be aggressive. Researchers found that this protein was present in some malignant tumors, especially in a type called anaplastic carcinoma. They created a new cell line from one of these tumors to study how S100A4 affects tumor growth and movement. When they reduced the levels of S100A4 in these cells, they noticed that the cells grew slower and moved less. This suggests that S100A4 might play a role in how these tumors develop and spread.
People also search for: dog mammary tumor treatment · S100A4 in canine cancer · anaplastic carcinoma in dogs · dog cancer cell growth factors
Abstract
S100A4 (metastasin), a member of the S100 protein family, was initially identified in metastatic cells and is well established as a marker of aggressive human cancer. However, expression and roles of S100A4 in canine mammary tumors have not been clarified. In this study, expression of S100A4 was examined immunohistochemically in normal, hyperplastic, and neoplastic mammary glands of dogs. In all normal and benign lesions, S100A4 was restricted to a few stromal fibroblasts and inflammatory cells. However, in 7 of 57 (12%) of the malignant tumors examined, cytoplasmic and nuclear expression of S100A4 was observed in epithelial tumor cells and stromal cells. Particularly, the frequency of S100A4-positive anaplastic carcinomas was high (4/8 cases, 50%). Next, we established a novel cell line, named NV-CML, from a S100A4-positive canine mammary carcinoma. The cultured NV-CML cells and the tumors that developed in the immunodeficient mice after subcutaneous injection of the cells maintained the immunophenotype of the original tumor, including S100A4 expression. Using this cell line, we examined the cellular functions of S100A4 using RNA interference. S100A4 expression level in NV-CML cells transfected with small interfering RNA (siRNA) targeting canine S100A4 (siS100A4) was reduced to about one-fifth of those with negative-control siRNA (siNeg). Cell proliferation in WST-8 assay and cell migration in Boyden chamber assay were significantly decreased in siS100A4-transfected cells compared with siNeg-transfected cells. These findings suggest that S100A4 may be related to progression of canine mammary carcinomas via its influence on cell growth and motility.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30686112/